The company is facing losing patent protection on drugs that accounted for 74 percent of its sales in 2009.
By DUFF WILSON, New York Times
Thu, 09/30/2010 - 8:27pm
The company is facing losing patent protection on drugs that accounted for 74 percent of its sales in 2009.